Holen Sie sich die Stockscreener-App
4.00
3.90%
0.15
Handel nachbörslich:
3.91
-0.09
-2.25%
Schlusskurs vom Vortag:
$3.85
Offen:
$3.85
24-Stunden-Volumen:
27,911
Relative Volume:
0.22
Marktkapitalisierung:
$7.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-1.23%
1M Leistung:
-11.70%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.8416
$4.04
1-Wochen-Bereich:
$3.63
$4.13
52-Wochen-Spanne:
$3.50
$5.44
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Quantum Biopharma Ltd Aktie (QNTM) Neueste Nachrichten
Quantum Biopharma Provides Corporate Update - Bluefield Daily Telegraph
Quantum Biopharma Provides Corporate Update - AccessWire
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US - Chronicle-Tribune
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US - AccessWire
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US - Newswire
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Invesments and Kingswood US - StockTitan
Investor.News Prepares for the ArcStone-Kingswood Growth Summit 2024 - InvestorNews Inc.
Quantum BioPharma Closes Private Placement Offering - Invezz
Quantum BioPharma Closes Private Placement Offering - Newsfile
QUANTUM BIOPHAR (QNTM) Upgraded to Buy: Here's What You Should Know - MSN
Quantum BioPharma Ltd. announced that it has received CAD 0.000036 million in funding from Fortius Research and Trading Corporation, Xorax Family Trust - Marketscreener.com
QUANTUM BIOPHAR (QNTM) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Quantum BioPharma to run multiple sclerosis progression study | 2024-09-09 | Investing News - Stockhouse Publishing
Quantum BioPharma partners for multiple sclerosis study - Investing.com
Quantum BioPharma partners for multiple sclerosis study - Investing.com India
S&P 500 Materials [Sector] (SRMA) QuotePress Release - The Globe and Mail
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis - Digital Journal
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease - PharmiWeb.com
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis - AccessWire
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis - Nasdaq
The Globe and Mail - The Globe and Mail
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis - StockTitan
ArcanaBio Secures Funding from BioInnovation Institute to Revolutionize Healthcare with new Ultra-Rapid Liquid Biopsy Technology - Via Ritzau
Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements - AccessWire
Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements - Newswire
Quantum BioPharma (QNTM) Experiences Pre-Market Boost - Stocks Telegraph
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Benzinga
QNTM Stock: Exploring Quantum BioPharma Ltd.’s Growth - The InvestChronicle
AusBiotech cohosts Quantum Meets Health workshop - Biotech Dispatch
Understanding QNTM stock ratios for better investment decisions - US Post News
Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80 - Big News Network
Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80 - AccessWire
Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80 - Yahoo Finance
August Wrap-up; New Stocks in biotech, transportation, tech, mining and defense - Investorideas.com newswire
Quantum Biopharma Announces Celly Nutrition Launches unbuzzd(TM) Grab-and-Go Stick Packs on Amazon.com so you can "own NOW and what’s NEXT" - AccessWire
Celly Nutrition Launches unbuzzd Grab-and-Go Stick Packs on Amazon.com so You Can "Own Now and What's Next" - Newsfile
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Quantum Announces Reverse Stock Split - Yahoo Finance
Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update - AccessWire
Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update - Chronicle-Tribune
Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update - Nasdaq
InvestmentPitch Media Video Discusses FSD Pharma and Construction of its Heritage Museum and Flagship Dispensary at the Former Kraft Plant in OntarioVideo Available on Investmentpitch.com - Marketscreener.com
Qubit Pharmaceuticals nominated for "Best start-up" award at Prix Galien USA 2024 - Yahoo Finance
In the Green: Quantum BioPharma Ltd. (QNTM) Closes at 4.27, Up/Down 0.00 from Previous Day - The Dwinnex
Quantum BioPharma (XCNQ:QNTM) EPS (Basic) : C$-22.62 (TTM As of Mar. 2024) - GuruFocus.com
Quantum BioPharma (XCNQ:QNTM) Dividend Payout Ratio : 0.00 (As of Mar. 2024) - GuruFocus.com
Quantum BioPharma (XCNQ:QNTM) Dividends per Share : C$0.00 (TTM As of Mar. 2024) - GuruFocus.com
Quantum BioPharma (XCNQ:QNTM) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
Quantum BioPharma (XCNQ:QNTM) Short-Term Debt & Capital Lea - GuruFocus.com
Quantum BioPharma (STU:0K91) EV-to-Revenue : (As of Aug. 17, 2024) - GuruFocus.com
QNTM (Quantum BioPharma) EV-to-Revenue : (As of Aug. 16, 2024) - GuruFocus.com
Finanzdaten der Quantum Biopharma Ltd-Aktie (QNTM)
Es liegen keine Finanzdaten für Quantum Biopharma Ltd (QNTM) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.23%
0.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):